FSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nFSD Pharma Adds Two More Prominent Cannabis Researchers to Scientific Advisory Board\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, June 6, 2019\n\n\n\n– Ziva Cooper, Ph.D. and Mallory Loflin, Ph.D. become latest members of the renowned group of FSD Scientific Advisors led by Charles Pollack, Jr. MD, FACEP\n TORONTO, June 6, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (\"FSD\" or the \"Company\"), is pleased to announce the addition of two distinguished cannabis researchers to the company's Scientific Advisory Board (\"SAB\").\n\n \n \n\n \n\"It is with great pride that we welcome Dr. Ziva Cooper and Dr. Mallory Loflin to our Scientific Advisory Board. The board, which also includes Dr. Daniel Piomelli and Dr. Ryan Vandrey, is shaping into a very robust body of scientists and researchers under the leadership of my good friend Dr. Pollack and I commend him for his leadership. We are counting on the invaluable input of our SAB members as we continue to explore the value add of potential applications of medicinal grade cannabis and synthetic cannabinoid pharmaceuticals,\" said Dr. Raza Bokhari, FSD Executive Co-Chairman & Chief Executive Officer.\nZiva Cooper, Ph.D., is the Research Director of UCLA's Cannabis Research Initiative in the Semel Institute for Neuroscience and Human Behavior in the Department of Psychiatry and Biobehavioral Sciences. Dr. Cooper has been overseeing and publishing studies investigating cannabis neurobiology and dependence for over 10 years, including studies examining the effects of these drugs on experimentally induced pain. After receiving her Ph.D. in Biopsychology in 2007 in the field of preclinical psychopharmacology, she moved to Columbia University to focus on translating preclinical studies of psychoactive substances to the clinic using controlled human drug-administration studies. Dr. Cooper's current resear...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B